China's Vincentage Unveils Oral Obesity Pill to Rival Pharma Giants

CHENGDU, China – May 18, 2026 – In a significant development for the global race to dominate the multi-billion dollar weight-loss market, Chengdu-based Vincentage Pharma announced overwhelmingly positive results for its oral obesity drug, VCT220. The successful Phase 3 trial positions the company to challenge Western pharmaceutical giants with a convenient, once-daily pill that could revolutionize treatment for millions in China and beyond.

Vincentage reported that its investigational GLP-1 receptor agonist achieved an average body weight reduction of up to 12.4% over 52 weeks in obese or overweight Chinese adults. The company now plans an imminent submission for a New Drug Application (NDA) to China’s National Medical Products Administration (NMPA), signaling a major step forward for domestically developed innovation in a field largely defined by injectable therapies.

A New Contender in the Global Drug Race

The announcement places VCT220 in the global spotlight, making it only the second oral non-peptide small-molecule GLP-1 drug to complete a pivotal Phase 3 trial for obesity, closely following orforglipron from U.S. behemoth Eli Lilly. This achievement marks a milestone for China's burgeoning biotech sector and for Vincentage, a company founded just five years ago in 2021.

The global market for GLP-1 therapies is projected to soar past $100 billion by 2030, driven by staggering demand for effective treatments for obesity and diabetes. While injectable drugs like Ozempic and Wegovy have become household names, the industry has been aggressively pursuing an oral "holy grail"—a pill that can offer similar efficacy without the need for needles.

"VCT220 is the second oral non-peptide small-molecule GLP-1 RA globally to complete a pivotal Phase 3 clinical trial for the treatment of obesity and ready for NDA submission," said Professor Ji Linong, the principal investigator for the drug's clinical trials and Director of Endocrinology at Peking University People's Hospital. "I am extremely proud to have been part of the full clinical development journey of this novel, non-peptide GLP-1 RA with an entirely new molecular structure, independently developed by a Chinese pharmaceutical company."

The trial data appears competitive. The 840-participant study showed that patients on higher doses of VCT220 lost an average of 12.4% of their body weight after one year, compared to just 1.3% for those on a placebo. This efficacy is in the same league as other oral GLP-1 candidates, positioning VCT220 as a formidable future competitor.

Beyond the Needle: An Oral Solution for China's Health Crisis

The true impact of VCT220 may be its potential to address China's escalating obesity crisis with unprecedented convenience. China is home to the world's largest overweight and obese population, with recent data indicating that nearly 35% of adults are overweight and over 14% are obese. This trend has created a massive, and largely underserved, public health challenge.

Until recently, treatment options were limited, but the market is now heating up. Novo Nordisk’s oral GLP-1, Rybelsus, was approved in China in 2024, and domestic players like Innovent Biologics have also entered the fray. VCT220, however, aims to stand out with its user-friendly profile.

According to Vincentage, the small-molecule pill is designed for once-daily administration without restrictions on food or water intake. It also does not require refrigeration or protection from light, removing significant logistical hurdles that can hinder patient adherence to other treatments.

"We believe VCT220 has the potential to provide a more convenient, accessible, and sustainable treatment option compared to injectable therapies," said Ben Li, Ph.D., Chief Executive Officer of Vincentage. He noted this could "help improve treatment initiation and long-term adherence," which are critical for managing a chronic condition like obesity.

Furthermore, the drug demonstrated a favorable safety profile. The most common side effects were gastrointestinal in nature and typically mild to moderate, subsiding after the initial dose-escalation period. Crucially, discontinuation rates due to side effects were very low at just 1.8%, suggesting patients found the treatment tolerable for long-term use.

Reshaping the Market from Chengdu to the World

While the initial focus is on the vast Chinese market, Vincentage has its sights set on the global stage. In a strategic move, the company partnered with Corxel Pharmaceuticals in November 2024, granting the global biotech firm development and commercialization rights for VCT220 outside of Greater China.

Under the partnership, Corxel is developing the drug under the program name CX11. A U.S.-based Phase 2 trial for obesity is already underway, with a readout expected later this year. This trans-pacific collaboration underscores the growing influence of Chinese biotech innovation and provides a clear pathway for VCT220 to reach patients worldwide, should it gain further regulatory approvals.

The success of VCT220 is a testament to Vincentage's focused strategy. The company has rapidly built a pipeline of oral small-molecule therapies targeting metabolic diseases like obesity, hypertension, and type 2 diabetes. The strong clinical data for VCT220 not only validates their discovery platform but also positions them as a serious player in one of medicine's most competitive and lucrative fields.

The company is also exploring the drug's potential beyond weight loss. Citing "significant blood pressure improvements" observed across its trials, Vincentage has already initiated new studies to evaluate VCT220 as a treatment for hypertension. This expanded focus could dramatically increase the drug's clinical and commercial value, offering an integrated solution for patients grappling with multiple, interconnected metabolic conditions. With its NDA submission on the horizon, the journey for this homegrown Chinese pill is just beginning.